Search Results
Your search for Matthew Stenger matches 7653 pages
Showing 3051 - 3100First-Line Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for SCLC Brain Metastases
In a cohort analysis reported in JAMA Oncology, Rusthoven et al found that first-line stereotactic radiosurgery was associated with similar outcomes as whole-brain radiotherapy in patients with small cell lung cancer (SCLC) brain metastases. As stated by the investigators, “Although stereotactic...
Impact of Medicare OCM Reporting Requirements on Biomarker Testing and Treatment in Advanced NSCLC
In a study reported in JCO Oncology Practice, Emily H. Castellanos, MD, MPH, and colleagues found that the requirement for Medicare Oncology Care Model (OCM) practices to report biomarker testing of patients with advanced non–small cell lung cancer (NSCLC) has not substantially altered the...
UKCCMP Prospective Cohort Study of COVID-19 Mortality in Patients With Cancer
As reported by Lee et al in The Lancet, a prospective cohort study from the United Kingdom performed by the UK Coronavirus Cancer Monitoring Project (UKCCMP) has found that increased risk of COVID-19 mortality in patients with cancer is associated with such factors as age, sex, and comorbidities,...
Role of Genetic Mutations and Treatment Exposures in Increased Subsequent Malignancy Risk for Childhood Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Qin et al identified combinations of pathogenic germline mutations in DNA repair genes and cancer treatment exposures that increased risk of subsequent neoplasms in long-term survivors of childhood cancer. Study Details The study involved...
Tafasitamab Plus Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In the phase II L-MIND trial reported in The Lancet Oncology, Gilles Salles, MD, and colleagues found that the combination of the Fc-enhanced anti-CD19 monoclonal antibody tafasitamab plus lenalidomide produced responses in patients with relapsed or refractory diffuse large B-cell lymphoma...
Ripretinib in Previously Treated Patients With Advanced GIST: INVICTUS Trial
As reported in The Lancet Oncology by Jean-Yves Blay, MD, and colleagues, the phase III INVICTUS trial has shown that the oral KIT and PDGFRα tyrosine kinase inhibitor ripretinib prolonged progression-free survival vs placebo in patients with advanced gastrointestinal stromal tumors (GIST) whose...
HLA-DP Expression and Risk of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation
In a study reported in the Journal of Clinical Oncology, Petersdorf et al found that level of expression of patient HLA-DPB1 mismatches and number of mismatches affect risk of acute graft-vs-host disease (GVHD) after unrelated donor hematopoietic cell transplantation. Study Details The study...
Retrospective Study of Characteristics and Outcomes in Patients With Cancer Hospitalized With COVID-19 in Hubei
In a retrospective cohort study reported in The Lancet Oncology, Yang et al described clinical characteristics, outcomes, and risk factors for mortality in patients with cancer hospitalized with COVID-19 over a 2-month period in Hubei, China. Study Details The study included 205 patients with...
Stereotactic Ablative Radiotherapy for Oligometastatic Cancer: Long-Term Findings From the SABR-COMET Trial
In a long-term follow-up of the phase II SABR-COMET trial reported in the Journal of Clinical Oncology, David A. Palma, MD, PhD, and colleagues found that the addition of stereotactic ablative radiotherapy (SABR) to palliative standard-of-care treatment in patients with oligometastatic cancers...
First-Line Osimertinib/Bevacizumab for Metastatic EGFR-Mutant Lung Cancer
In the phase II portion of a single-center phase I/II trial reported in JAMA Oncology, Yu et al found that the combination of first-line osimertinib and bevacizumab resulted in a high rate of 1-year progression-free survival in patients with metastatic EGFR-mutant lung cancer. As stated by the...
Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma
In a study presented at the ASCO20 Virtual Scientific Program (Abstract 5077) and published as a brief report in JAMA Oncology, Ravi et al found that rechallenge with immune checkpoint inhibitor therapy was capable of producing responses in patients with metastatic renal cell carcinoma, including...
FGFR1–3 Inhibitor AZD4547 in Refractory Tumors Harboring FGFR Activating Mutations and Fusions
As reported in the Journal of Clinical Oncology by Chae et al, findings in a cohort of the phase II NCI-MATCH trial (EAY131, Subprotocol W) indicated that the oral inhibitor of fibroblast growth factor receptor 1, 2, and 3 (FGFR1–3), AZD4547, produced a small number of responses in patients with a...
Acalabrutinib vs Idelalisib/Rituximab or Bendamustine/Rituximab for Relapsed or Refractory CLL: ASCEND Trial
As reported in the Journal of Clinical Oncology by Ghia et al, the phase III ASCEND trial has shown prolonged progression-free survival with acalabrutinib monotherapy vs investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in adult patients with relapsed or refractory...
Factors Associated With All-Cause 30-Day Mortality in Patients With Cancer Infected With COVID-19: CCC19 Database Analysis
As reported in The Lancet by Jeremy L. Warner, MD, and colleagues, a cohort study using the COVID-19 and Cancer Consortium (CCC19) database has shown that increased risk of all-cause mortality in patients with cancer infected with COVID-19 is associated with such factors as increased age, male sex, ...
Addition of Pemetrexed vs Vinorelbine to Adjuvant Cisplatin for Nonsquamous NSCLC
In the Japanese phase III JIPANG trial reported in the Journal of Clinical Oncology, Kenmotsu et al found that adjuvant therapy with pemetrexed/cisplatin did not result in superior recurrence-free survival but was better tolerated than vinorelbine/cisplatin in patients with completely resected...
Pembrolizumab Plus Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
In a phase Ib study reported in the Journal of Clinical Oncology, Powell et al found that the addition of pembrolizumab to curative chemoradiotherapy was safe and associated with response in patients with locally advanced head and neck squamous cell carcinoma. Study Details The U.S. multicenter...
Meta-analysis of Outcomes With Checkpoint Inhibitor Treatment in Advanced Microsatellite Instability–High Cancers
A meta-analysis of published studies of immune checkpoint inhibition for advanced microsatellite instability–high (MSI-H) cancers—published as a brief report in JAMA Oncology by Petrelli et al—found high activity of these therapies across tumor types and evaluated agents. Study Details The...
Real-World Outcomes With Axicabtagene Ciloleucel Therapy in Relapsed or Refractory Large B-Cell Lymphoma
In a retrospective study reported by Nastoupil et al in the Journal of Clinical Oncology, researchers in the U.S. Lymphoma CAR T Consortium described outcomes with standard-of-care use of the autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel in patients ...
Breastfeeding Associated With Reduced Risk of Invasive Ovarian Cancer, Including High-Grade Serous Disease
In a pooled analysis reported in JAMA Oncology,1 Naoko Sasamoto, MD, MPH, of the Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Boston, and colleagues found that breastfeeding, even for durations of 1 to 3 months per birth, was associated with a significant reduction...
Niraparib for First-Line Maintenance Treatment of Advanced Ovarian Cancer
On April 29, 2020, niraparib was approved for maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.1,2 Supporting Efficacy Data Approval was based on...
Selpercatinib for Lung and Thyroid Cancers With RET Gene Mutations or Fusions
On may 8, 2020, selpercatinib was granted accelerated approval for the following indications: Adult patients with metastatic RET fusion-positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who...
Ibrutinib in Combination With Rituximab in Chronic Lymphocytic Leukemia
On April 21, 2020, ibrutinib was granted an expanded indication for use in combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1,2 The recommended dosage of ibrutinib in CLL/SLL is 420 mg, once daily,...
Olaparib Plus Bevacizumab in Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
On May 8, 2020, olaparib was granted an expanded indication to include use in combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line...
Safety and Patient-Reported Outcomes From the IMpower150 Trial in Metastatic Nonsquamous NSCLC
A safety and patient-reported outcome analysis from the IMpower150 trial, reported in the Journal of Clinical Oncology by Martin Reck, PhD, and colleagues, indicated that atezolizumab plus bevacizumab and chemotherapy appeared to be a manageable and tolerable regimen when compared with atezolizumab ...
Outcomes With Minimally Invasive vs Open Esophagectomy in Routine Practice
In a Dutch study reported in the Journal of Clinical Oncology, Markar et al found that routine use of minimally invasive vs open esophagectomy for esophageal cancer was associated with increased risk of pulmonary complications and other adverse outcomes, contrary to the findings of the clinical...
Impact of the COVID-19 Pandemic on Pediatric Cancer Care in Latin America
In a commentary published in The Lancet Oncology, Vasquez et al presented results of a survey of pediatric oncologists/hematologists across Latin America, which showed an adverse early impact of the COVID-19 pandemic on pediatric cancer care. Study Details The study included a cross-sectional...
Sacituzumab Govitecan-hziy for Previously Treated Metastatic Triple-Negative Breast Cancer
On April 22, 2020, the antibody-drug conjugate sacituzumab govitecan-hziy was granted accelerated approval for treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.1,2 Supporting Efficacy Data Approval was...
Presalvage Radiotherapy PSA Levels and Outcomes With Long-Term Antiandrogen Therapy in Prostate Cancer
In an analysis from the NRG/RTOG 9601 trial reported in JAMA Oncology,1Robert T. Dess, MD, of the Department of Radiation Oncology, University of Michigan, Ann Arbor, and colleagues found that men with higher prostate-specific antigen (PSA) presalvage radiotherapy levels after prostatectomy had a...
Nivolumab vs Bevacizumab in Recurrent Glioblastoma
As reported in JAMA Oncology by David A. Reardon, MD, and colleagues, the phase III CheckMate 143 trial showed no difference in overall survival among adult patients with a first recurrence of glioblastoma treated with nivolumab vs bevacizumab following standard radiation and temozolomide therapy. ...
Pembrolizumab, Trastuzumab, and Chemotherapy in HER2-Positive Metastatic Esophagogastric Cancer
In a single-center phase II trial reported in The Lancet Oncology, Janjigian et al found that the addition of pembrolizumab to trastuzumab and chemotherapy showed activity in the first-line treatment of HER2-positive metastatic esophagogastric cancer. Study Details The investigator-initiated trial...
Genomic Characteristics of Smoldering Multiple Myeloma and Risk of Progression
In a study reported in the Journal of Clinical Oncology, Mark Bustoros, MD, and colleagues identified genomic features of smoldering multiple myeloma associated with a higher risk of progression to multiple myeloma and found that alterations that drive disease progression are already present at the ...
Risk-Adapted Dose-Adjusted EPOCH-R for Previously Untreated Adult Patients With Burkitt Lymphoma
In a phase II study reported in the Journal of Clinical Oncology, Roschewski et al found that risk-adapted dose-adjusted etoposide doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (EPOCH-R) produced high event-free survival rates among high- and low-risk adult patients with...
Adjuvant Nivolumab/Ipilimumab or Nivolumab Alone vs Placebo in Patients With Resected Stage IV Melanoma
In an interim analysis of the German phase II IMMUNED study reported in The Lancet, Zimmer et al found that adjuvant therapy with nivolumab/ipilimumab or nivolumab alone significantly prolonged recurrence-free survival vs placebo in patients with resected stage IV melanoma and no evidence of...
Trastuzumab Deruxtecan vs Chemotherapy for Previously Treated Patients With HER2-Positive Advanced Gastric Cancer
Results of the phase II DESTINY-Gastric01 study—reported at the ASCO20 Virtual Scientific Program (Abstract 4513) and published in The New England Journal of Medicine, by Kohei Shitara, MD, of the National Cancer Center Hospital East, Kashiwa, and colleagues—found that the antibody-drug conjugate...
Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial
As reported at the ASCO20 Virtual Scientific Program (Abstract 5602) and in The New England Journal of Medicine by Shore et al, the phase III HERO trial showed sustained castrate testosterone levels and lower risk of major cardiovascular events with the oral gonadotropin-releasing hormone...
Does Treatment With Immune Checkpoint Inhibitors Cause Flare-ups in Patients With Preexisting IBD or Microscopic Colitis?
In a retrospective analysis reported in JCO Oncology Practice, Grover et al found that enterocolitis flares occurred in approximately one-quarter of patients with preexisting inflammatory bowel disease (IBD) or microscopic colitis who received immune checkpoint inhibitors for the treatment of solid ...
Liposomal Daunorubicin and Cytarabine Followed by FLAG for Pediatric Relapsed AML
In a phase I/II Children’s Oncology Group study (AAML1421) reported in the Journal of Clinical Oncology, Cooper et al identified the phase II dose of CPX-351, a liposomal preparation of daunorubicin and cytarabine, and found that a regimen consisting of CPX-351 followed by fludarabine, cytarabine,...
Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer
In the final overall survival analysis of the phase III PROSPER trial reported at the ASCO20 Virtual Scientific Program (Abstract 5515) and published in The New England Journal of Medicine, Cora N. Sternberg, MD, and colleagues found that enzalutamide plus androgen-deprivation therapy (ADT)...
Standard vs Histology-Tailored Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcoma
As reported in the Journal of Clinical Oncology by Alessandro Gronchi, MD, and colleagues, final results of a phase III trial conducted by the Italian, French, and Polish Sarcoma Groups showed no disease-free or overall survival benefit with use of histology-tailored vs standard...
IMvigor130: First-Line Atezolizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced Urothelial Cancer
As reported in The Lancet by Matthew D. Galsky, MD, of Icahn School of Medicine at Mount Sinai, and colleagues, the phase III IMvigor130 trial has shown prolonged progression-free survival with first-line atezolizumab plus platinum-based chemotherapy vs platinum-based chemotherapy alone in patients ...
First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer
As reported at the ASCO20 Virtual Scientific Program by Charles M. Rudin, MD, PhD, and colleagues (Abstract 9001), the phase III KEYNOTE-604 trial has shown that first-line pembrolizumab plus etoposide/platinum significantly prolonged progression-free survival and prolonged overall survival at a...
Tucatinib Combination in Previously Treated HER2-Positive Metastatic Breast Cancer With Brain Metastases
In an analysis of the pivotal phase III HER2CLIMB trial to be reported at the ASCO20 Virtual Scientific Program, Nancy U. Lin, MD, and colleagues found that tucatinib, a small-molecule tyrosine kinase inhibitor that is highly selective for HER2, plus trastuzumab/capecitabine significantly improved...
Sources for Better GVHD-Free Relapse-Free Survival After Adult Alternative Donor HCT
In a retrospective study of registry data reported in the Journal of Clinical Oncology, Mehta et al identified alternative donor sources for hematopoietic cell transplantation (HCT) that were associated with better graft-vs-host disease (GVHD)-free (GRFS) and chronic GVHD–free (CRFS) relapse-free...
Use of Symptom Assessment Scale vs Routine Management in Patients With Cancer Receiving Radiotherapy
In a single-institution study reported in JCO Oncology Practice, Goyal et al found that use of the Edmonton Symptom Assessment Scale (ESAS) self-assessment tool during weekly on-treatment physician visits was associated with reduced symptom severity vs routine symptom management in patients...
Ivosidenib for IDH1-Mutant Chemotherapy-Refractory Cholangiocarcinoma
As reported by Ghassan K. Abou-Alfa, MD, and colleagues in The Lancet Oncology, the phase III ClarIDHy trial has shown that the isocitrate dehydrogenase-1 (IDH1) inhibitor ivosidenib improved progression-free survival vs placebo in patients with advanced IDH1-mutant chemotherapy-refractory...
Tucatinib in Previously Treated HER2-Positive Metastatic Breast Cancer
On April 17, 2020, tucatinib was approved for use in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. These patients included those with brain metastases and those who have received one or more prior...
Mitomycin Gel for Low-Grade Upper Tract Urothelial Cancer
On April 15, 2020, mitomycin gel was approved for the treatment of adult patients with low-grade upper tract urothelial cancer.1,2 Mitomycin gel is for pyelocalyceal use alone and not for intravenous, topical, or oral administration. Supporting Efficacy Data Approval was based on findings in the...
Luspatercept-aamt for Anemia in Adults With Myelodysplastic Syndromes
On April 3, 2020, luspatercept-aamt was approved in the treatment of anemia failing to respond to an erythropoiesis-stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks.1,2 The treatment is geared toward adult patients with very low– to intermediate-risk myelodysplastic ...
Selumetinib for Pediatric Neurofibromatosis Type 1 With Symptomatic, Inoperable Plexiform Neurofibromas
On April 10, 2020, the oral MEK inhibitor selumetinib was approved for the treatment of patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.1,2 Selumetinib is the first therapy approved for children who have this disease....
